Loading
A phase 3 trial of Cadonilimab in hepatocellular carcinoma, run by Akeso, now recruiting.
A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection is a phase 3 interventional study registered as NCT05489289 by Akeso, with 570 participants planned, started 2023-01-05 and due to reach its primary completion in 2026-01-28. Interventions recorded: AK104, placebo. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Cadonilimab, Akeso, Bispecific antibodies, Hepatocellular carcinoma.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Cadonilimab, Akeso, Bispecific antibodies, Hepatocellular carcinoma.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/